Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies for patients with cancer and other incurable diseases. Its lead product candidate, anitocabtagene autoleuce... Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies for patients with cancer and other incurable diseases. Its lead product candidate, anitocabtagene autoleucel (anito-cel), utilizes the proprietary ddCAR platform and is in phase 3 clinical trials for relapsed or refractory multiple myeloma, featuring D-Domain technology for enhanced control and safety. The company advances ACLX-001, targeting BCMA in phase 1 for the same indication via the ARC-SparX platform, and ACLX-002 in phase 1 against CD123 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Preclinical efforts include ACLX-003 for AML and MDS, alongside programs for solid tumors. Arcellx maintains a strategic collaboration with Kite Pharma, a Gilead company, to co-develop and co-commercialize anito-cel. Founded in 2014 and headquartered in Redwood City, California, Arcellx focuses on engineering safer, more effective, and accessible immunotherapies to transform cancer treatment.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Greenhouse Gas (GHG) Emissions data disclosed by Arcellx

We reviewed Arcellx's website and available disclosure materials for the 2023 reporting period and did not identify any reported Greenhouse Gas (GHG) Emissions data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Arcellx's data?

Start your 30-day free trial to request a data review for Arcellx.

Start Free Trial

Legal Center Contact Us

Arcellx Inc

No Greenhouse Gas (GHG) Emissions data disclosed by Arcellx

Account Restricted